Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 06 MARCH 2025

CTA Update - March 2, 2025

Fairfield and Woods
Explore more from Fairfield and Woods

On March 2, 2025, the Treasury Department announced it will not enforce any penalties or fines associated with the Beneficial Ownership Information (BOI) reporting rule under the existing regulatory deadlines...

United StatesCorporate/Commercial Law
Gil Selinger
Gil Selinger
Author LinkedIn connections

On March 2, 2025, the Treasury Department announced it will not enforce any penalties or fines associated with the Beneficial Ownership Information (BOI) reporting rule under the existing regulatory deadlines, and further not enforce any penalties or fines against U.S. citizens or domestic reporting companies or their beneficial owners after the rule changes take effect. The Treasury also announced that it will further issue a proposed rulemaking that will narrow the scope of the rule to foreign reporting companies only.

We expect an interim rule to be proposed on March 21, 2025, but the timing of its effectiveness as well as any public comment period is unknown. Additionally, there are currently two bills in Congress that aim to overturn the law.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP